Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75443
UPID:
TECTA_HUMAN
Alternative names:
-
Alternative UPACC:
O75443
Background:
Alpha-tectorin plays a pivotal role in hearing by being a major non-collagenous component of the tectorial membrane in the inner ear. This membrane is crucial for sound transduction, interacting directly with sensory hair cells to convert sound waves into electrical signals.
Therapeutic significance:
Given its critical function in hearing, mutations in Alpha-tectorin are linked to autosomal dominant and recessive forms of non-syndromic sensorineural hearing loss. Understanding the role of Alpha-tectorin could open doors to potential therapeutic strategies for these hearing impairments.